Contemporary management of high-risk localized prostate cancer

Current Urology Reports

Volumn 11, Issue 3, 2010, Pages 159-164

  Garzotto, Mark ^a   Hung, Arthur Y ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adjuvant; Androgens; Chemotherapy; Gleason score; Neoadjuvant; Prostate cancer; Prostatectomy; Radiation

Indexed keywords

DOCETAXEL; MITOXANTRONE; OGX 011; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOTHERAPY; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; MALE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952236883     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0101-0     Document Type: Review

References (54)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. PC Albertsen JA Hanley J Fine 2005 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2095 2101 10.1001/jama.293.17.2095 1:CAS:528:DC%2BD2MXjvFGqt7s%3D 15870412 (Pubitemid 40617061)
3. GL Andriole ED Crawford RL Grubb 3rd, et al. 2009 Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 1310 1319 10.1056/NEJMoa0810696 1:CAS:528:DC%2BD1MXjs1ejsLk%3D 19297565
4. FH Schroder J Hugosson MJ Roobol, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 1320 1328 10.1056/NEJMoa0810084 19297566
5. AV D'Amico R Whittington SB Malkowicz, et al. 1998 Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 969 974 10.1001/jama.280.11.969 9749478 (Pubitemid 28445094)
6. AJ Stephenson PT Scardino JA Eastham, et al. 2005 Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 7005 7012 10.1200/JCO.2005.01.867 16192588 (Pubitemid 46260287)
7. Memorial Sloan-Kettering Cancer Center: Prediction tools: a tool for doctors and patients. Available at http://www.mskcc.org/mskcc/html/5794.cfm. Accessed February 2010.
8. KL Greene PC Albertsen RJ Babaian, et al. 2009 Prostate specific antigen best practice statement: 2009 update J Urol 182 2232 2241 10.1016/j.juro.2009. 07.093 1:CAS:528:DC%2BD1MXhtlyqu7bF 19781717
9. JL Mohler 2010 The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer J Natl Compr Canc Netw 8 145 20141674
10. M Fuchsjager O Akin A Shukla-Dave, et al. 2009 The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer Clin Adv Hematol Oncol 7 193 202 19398944
11. MG Harisinghani J Barentsz PF Hahn, et al. 2003 Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 348 2491 2499 10.1056/NEJMoa022749 12815134 (Pubitemid 36706536)
12. W Huang X Li EA Morris, et al. 2008 The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo Proc Natl Acad Sci U S A 105 17943 17948 10.1073/pnas.0711226105 1:CAS:528:DC%2BD1cXhsVCrt7zJ 19004780
13. G Sonpavde KN Chi T Powles, et al. 2007 Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer Cancer 110 2628 2639 10.1002/cncr.23085 1:CAS:528:DC%2BD1cXitVOitg%3D%3D 17941029 This paper concisely outlines the rationale and outcomes of recent studies using the neoadjuvant approach for high-risk prostate cancer. Future implications of ongoing studies are discussed (Pubitemid 350250331)
14. WK Lau EJ Bergstralh ML Blute, et al. 2002 Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables J Urol 167 117 122 10.1016/S0022-5347(05)65394-3 11743287
15. CR Pound AW Partin MA Eisenberger, et al. 1999 Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1591 1597 10.1001/jama.281.17.1591 1:STN:280:DyaK1M3kvFagsg%3D%3D 10235151 (Pubitemid 29211767)
16. M Bolla L Collette L Blank, et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 103 106 10.1016/S0140-6736(02)09408-4 1:CAS:528:DC%2BD38Xlt1Ohuro%3D 12126818 (Pubitemid 34786197)
17. Roach M, Lu J, Pilepich MV, et al.: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000, 47:609-615. (Erratum appears in Int J Radiat Oncol Biol Phys 2000, 48:313 Note: Mohuidden M [corrected to Mohiuddin M].) (Pubitemid 30317478)
18. PC Walsh 2009 2008 Whitmore Lecture: radical prostatectomy-where we were and where we are going Urol Oncol 27 246 250 19414112
19. GW Hull F Rabbani F Abbas, et al. 2002 Cancer control with radical prostatectomy alone in 1, 000 consecutive patients J Urol 167 2 Pt 1 528 534 11792912 (Pubitemid 34074521)
20. JF Ward H Zincke EJ Bergstralh, et al. 2004 The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy J Urol 172 4 Pt 1 1328 1332 10.1097/01.ju.0000138681.64035.dc 15371834 (Pubitemid 39249708)
21. M Wagner M Sokoloff S Daneshmand 2008 The role of pelvic lymphadenectomy for prostate cancer-therapeutic? J Urol 179 408 413 10.1016/j.juro.2007.09.027 1:STN:280:DC%2BD1c%2Fjs1agtA%3D%3D 18076938
22. A Briganti ML Blute JH Eastham, et al. 2009 Pelvic lymph node dissection in prostate cancer Eur Urol 55 1251 1265 10.1016/j.eururo.2009.03.012 19297079 The importance of an adequate lymph node dissection for both staging and therapeutic reasons are discussed. A thorough understanding of pelvic anatomy with attention to the spread of metastases is essential to properly performing this component of the prostatectomy
23. AL Zietman ML DeSilvio JD Slater, et al. 2005 Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 1233 1239 10.1001/jama.294.10.1233 1:CAS:528:DC%2BD2MXpvFKhtLw%3D 16160131 (Pubitemid 41352111)
24. R de Crevoisier D Kuban D Lefkopoulos 2006 Image-guided radiotherapy by in-room CT-linear accelerator combination [in French] Cancer Radiother 10 245 251 16959518
25. CA Lawton K Winter K Murray, et al. 2001 Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 937 946 10.1016/S0360-3016(00)01516-9 1:STN:280:DC%2BD3M7osFajsQ%3D%3D 11240234 (Pubitemid 32184600)
26. M Bolla TM de Reijke G Van Tienhoven, et al. 2009 Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2516 2527 10.1056/NEJMoa0810095 1:CAS:528:DC%2BD1MXntVKqtr0%3D 19516032
27. EM Messing J Manola J Yao, et al. 2006 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 6 472 479 10.1016/S1470-2045(06)70700-8 In this study, 3 years of androgen deprivation was compared with 6 months of treatment after radiation. This showed definitive improvements in overall and PCSM without an increase in cardiovascular morbidity, favoring the 3-year arm (Pubitemid 43779173)
28. UE Studer P Whelan W Albrecht, et al. 2006 Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 1868 1876 10.1200/JCO.2005.04.7423 16622261 (Pubitemid 46638985)
29. G Aus PA Abrahamsson G Ahlgren, et al. 2002 Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial BJU Int 90 561 566 10.1046/j.1464-410X.2002.02982.x 1:CAS:528:DC%2BD38XotlGnt7c%3D 12230618
30. Gleave ME, Goldenberg SL, Chin JL, et al.: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500-506; discussion 506-507. (Pubitemid 32652231)
31. Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME: Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology 2002, 60(3 Suppl 1):45-51; discussion 51. (Pubitemid 35304541)
32. F Rabbani M Perrotti A Bastar WR Fair 1999 Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy J Urol 161 847 852 10.1016/S0022-5347(01)61788-9 1:CAS:528:DyaK1MXhtleisL8%3D 10022699 (Pubitemid 29422381)
33. MS Soloway K Pareek R Sharifi, et al. 2002 Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results J Urol 167 112 116 10.1016/S0022-5347(05)65393-1 11743286 (Pubitemid 34024512)
34. MV Pilepich K Winter MJ John, et al. 2001 Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 1243 1252 1:STN:280:DC%2BD3MvjslKruw%3D%3D 11483335 (Pubitemid 32727802)
35. A Nanda MH Chen MH Braccioforte, et al. 2009 Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 866 873 10.1001/jama.2009.1137 1:CAS:528:DC%2BD1MXhtVequrbK 19706860
36. H Hricak H Schoder D Pucar, et al. 2003 Advances in imaging in the postoperative patient with a rising prostate-specific antigen level Semin Oncol 30 616 634 10.1016/S0093-7754(03)00359-2 14571410 (Pubitemid 37296787)
37. V Scattoni F Montorsi M Picchio, et al. 2004 Diagnosis of local recurrence after radical prostatectomy BJU Int 93 680 688 10.1111/j.1464-410X. 2003.04692.x 1:STN:280:DC%2BD2c3jtFWitQ%3D%3D 15009088 (Pubitemid 38375788)
38. AJ Stephenson SF Shariat MJ Zelefsky, et al. 2004 Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy JAMA 291 1325 1332 10.1001/jama.291.11.1325 1:CAS:528:DC%2BD2cXitlKntr0%3D 15026399 (Pubitemid 38541647)
39. M Bolla H van Poppel L Collette, et al. 2005 Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 572 578 10.1016/S0140-6736(05)67101-2 16099293 (Pubitemid 41140332)
40. IM Thompson Jr CM Tangen J Paradelo, et al. 2006 Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2329 2335 10.1001/jama.296.19.2329 1:CAS:528:DC%2BD28Xht1ans7bF 17105795 (Pubitemid 44749360)
41. GP Swanson MA Hussey CM Tangen, et al. 2007 Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2225 2229 10.1200/JCO.2006.09.6495 17538167 (Pubitemid 46954647)
42. IM Thompson CM Tangen J Paradelo, et al. 2009 Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 956 962 10.1016/j.juro.2008.11.032 19167731
43. DP Petrylak CM Tangen MH Hussain, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520 10.1056/NEJMoa041318 1:CAS:528: DC%2BD2cXot1Kmu7c%3D 15470214 The above four papers highlight the need to improve upon local therapies for prostate cancer, as the risk of local recurrence is over 50% in high-risk cases (Pubitemid 39315318)
44. IF Tannock R de Wit WR Berry, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512 10.1056/NEJMoa040720 1:CAS:528:DC%2BD2cXot1Kmu7s%3D 15470213 (Pubitemid 39315317)
45. AR Patel HM Sandler KJ Pienta 2005 Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer Clin Genitourin Cancer 4 212 214 10.3816/CGC.2005.n.035 16425991
46. B Montgomery P Lavori M Garzotto, et al. 2008 Veterans Affairs Cooperative Studies Program study 553: chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer Urology 72 474 480 10.1016/j.urology.2008.02.050 18407333
47. M Hussain DC Smith BF El-Rayes, et al. 2003 Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer Urology 61 774 780 10.1016/S0090-4295(02)02519-0 12670564 (Pubitemid 36384972)
48. BR Konety JA Eastham VE Reuter, et al. 2004 Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study J Urol 171 2 Pt 1 709 713 10.1097/01.ju.0000108122.36893.5a 14713792 (Pubitemid 38090463)
49. KN Chi JL Chin E Winquist, et al. 2008 Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer J Urol 180 565 570 10.1016/j.juro.2008.04.012 1:CAS:528:DC%2BD1cXpsFyiu78%3D 18554663 discussion 570 (Pubitemid 351942412)
50. JA Eastham WK Kelly GD Grossfeld EJ Small 2003 Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease Urology 62 Suppl 1 55 62 10.1016/j.urology.2003.09. 052 14747042 (Pubitemid 41116563)
51. Garzotto M, Higano CS, O'Brien C, et al.: Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010 Feb 8 (Epub ahead of print).
52. DZ Qian CY Huang CA O'Brien, et al. 2009 Prostate cancer-associated gene expression alterations determined from needle biopsies Clin Cancer Res 15 3135 3142 10.1158/1078-0432.CCR-08-1982 1:CAS:528:DC%2BD1MXltFOrtbk%3D 19366833
53. DZ Qian BL Rademacher J Pittsenbarger, et al. 2010 CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity Prostate 70 433 442 1:CAS:528:DC%2BC3cXktlSmsbs%3D 19866475
54. Zoubeidi A, Chi K, Gleave M: Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res Feb 9 (Epub ahead of print).